Lorundrostat Trial Shows Promise for Kidney Disease
New clinical data reveals that the drug significantly lowers blood pressure and protein levels in patients with chronic kidney disease.
Updated on Oct. 22, 2026 in Heart Disease
Live Poll
Do you trust that new pharmaceutical treatments for chronic conditions effectively improve patient long-term health?
Mineralys Therapeutics presented Phase 3 trial data for its investigational drug lorundrostat at the American Society of Nephrology Kidney Week conference. The results demonstrate significant reductions in systolic blood pressure and urine albumin-to-creatinine levels among participants.
Why it matters
The study addresses the critical need for new treatments for patients with uncontrolled blood pressure and chronic kidney disease. By targeting dysregulated aldosterone levels, the drug offers a potential new mechanism to manage hypertension in this high-risk population.
In the Phase 3 Launch-HTN trial, lorundrostat demonstrated a 9.6 mmHg reduction in systolic blood pressure for participants with chronic kidney disease and a 12.2 mmHg reduction for those without. Additionally, patients with baseline albuminuria experienced a 52.2% reduction in their urine albumin-to-creatinine ratio.
The players
Mineralys Therapeutics
A clinical-stage biopharmaceutical company headquartered in Radnor, Pennsylvania, that focuses on developing therapies for hypertension.
American Society of Nephrology
A professional organization that hosted the Kidney Week 2026 conference where the clinical results were unveiled.
The details
Participants in the study were randomized to receive 50 mg of the aldosterone synthase inhibitor daily or a placebo, with some allowed to escalate to 100 mg. The study specifically tracked changes in systolic blood pressure from baseline over six weeks using automated office monitoring.
Timeline
October 22, 2026: Clinical trial data was presented at ASN Kidney Week in Denver.
December 22, 2026: The FDA is expected to complete its review of the drug.
Health Landscape
The presentation of these results at the ASN Kidney Week conference marks the latest milestone for Mineralys Therapeutics in the competitive field of hypertension drug development. This trial provides a significant addition to the existing clinical literature regarding aldosterone synthase inhibition for kidney disease management.
This development potentially offers patients with chronic kidney disease and uncontrolled blood pressure a new therapeutic option to manage their condition. If approved, the drug could eventually become a standard treatment for reducing cardiovascular and renal risks in this patient demographic.
The takeaway
The study highlights how targeted inhibition of aldosterone can lead to measurable clinical improvements in patients suffering from both kidney issues and hypertension. These results provide a clearer outlook for patients currently struggling to manage their blood pressure through conventional means.
What happens next
The U.S. Food and Drug Administration is scheduled to complete its review of the drug application for lorundrostat by December 22, 2026.
Further reading
For more information on clinical advancements in this field, visit the Heart Disease section.
Source note: This article includes information reported by The Manila times.
Live Poll
Do you trust that new pharmaceutical treatments for chronic conditions effectively improve patient long-term health?
